NASDAQ:ODT - Odonate Therapeutics Stock Price, Forecast & News

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ODT shares have increased by 0.1% and is now trading at $25.95. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Odonate Therapeutics.

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for Odonate Therapeutics.

Odonate Therapeutics Inc (NASDAQ:ODT) released its quarterly earnings results on Thursday, February, 20th. The company reported ($0.91) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.11. View Odonate Therapeutics' earnings history.

2 Wall Street analysts have issued 12-month target prices for Odonate Therapeutics' stock. Their forecasts range from $26.00 to $26.00. On average, they anticipate Odonate Therapeutics' stock price to reach $26.00 in the next year. This suggests a possible upside of 0.2% from the stock's current price. View analysts' price targets for Odonate Therapeutics.

Media stories about ODT stock have been trending extremely negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Odonate Therapeutics earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutOdonate Therapeutics.

Odonate Therapeutics saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 815,200 shares, a decline of 20.1% from the February 27th total of 1,020,000 shares. Based on an average daily volume of 66,400 shares, the short-interest ratio is presently 12.3 days. Approximately 2.8% of the company's stock are sold short. View Odonate Therapeutics' Current Options Chain.

Some companies that are related to Odonate Therapeutics include Mirati Therapeutics (MRTX), Evotec (EVTCY), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Emergent Biosolutions (EBS), FibroGen (FGEN), PTC Therapeutics (PTCT), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), Agios Pharmaceuticals (AGIO) and Ultragenyx Pharmaceutical (RARE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Five Prime Therapeutics (FPRX), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Bausch Health Companies (BHC) and Acorda Therapeutics (ACOR).

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Odonate Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (4.14%), Franklin Resources Inc. (3.71%), Franklin Resources Inc. (3.71%), Driehaus Capital Management LLC (2.07%), State Street Corp (0.75%) and Pictet Asset Management Ltd. (0.61%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View institutional ownership trends for Odonate Therapeutics.

ODT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Franklin Resources Inc., Oxford Asset Management LLP, Goldman Sachs Group Inc., California Public Employees Retirement System, Chartwell Investment Partners LLC, and Spark Investment Management LLC. View insider buying and selling activity for Odonate Therapeutics.

ODT stock was acquired by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Pictet Asset Management Ltd., State Street Corp, Janus Henderson Group PLC, Virtus ETF Advisers LLC, AQR Capital Management LLC, UBS Group AG, and Bank of New York Mellon Corp. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang. View insider buying and selling activity for Odonate Therapeutics.

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ODT stock can currently be purchased for approximately $25.95.

Odonate Therapeutics has a market capitalization of $831.96 million. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe. View additional information about Odonate Therapeutics.

The official website for Odonate Therapeutics is http://www.odonate.com/.

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]